177 related articles for article (PubMed ID: 36949044)
1. YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells.
Bai Y; Gotz C; Chincarini G; Zhao Z; Slaney C; Boath J; Furic L; Angel C; Jane SM; Phillips WA; Stacker SA; Farah CS; Darido C
Nat Commun; 2023 Mar; 14(1):1591. PubMed ID: 36949044
[TBL] [Abstract][Full Text] [Related]
2. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
Hussain SA; Venkatesh T
Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
4. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
5. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
6. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
7. Daidzin targets epithelial-to-mesenchymal transition process by attenuating manganese superoxide dismutase expression and PI3K/Akt/mTOR activation in tumor cells.
Yang MH; Jung SH; Um JY; Kumar AP; Sethi G; Ahn KS
Life Sci; 2022 Apr; 295():120395. PubMed ID: 35181309
[TBL] [Abstract][Full Text] [Related]
8. Effecacy of Biejia (Carapax Trionycis) and Ezhu (Rhizoma Curcumae Phaeocaulis) couplet medicine on epithelial-mesenchymal transition, invasion and migration of MDA-MB-231 triple negative breast cancer cells via PI3K/Akt/mTOR signaling pathway.
Zhu MJ; Xie S; Xie Q; Zhu JL; Huang YZ
J Tradit Chin Med; 2021 Dec; 41(6):853-861. PubMed ID: 34939381
[TBL] [Abstract][Full Text] [Related]
9. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway.
Hu J; Li G; Liu Z; Ma H; Yuan W; Lu Z; Zhang D; Ling H; Zhang F; Liu Y; Liu C; Qiu Y
Mol Carcinog; 2023 May; 62(5):628-640. PubMed ID: 36727616
[TBL] [Abstract][Full Text] [Related]
10. TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway.
Gao X; Jiang W; Ke Z; Huang Q; Chen L; Zhang G; Li C; Yu X
Biochem Biophys Res Commun; 2022 Jan; 586():34-41. PubMed ID: 34826698
[TBL] [Abstract][Full Text] [Related]
11. Ginkgolic Acid Inhibits Invasion and Migration and TGF-β-Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation.
Baek SH; Ko JH; Lee JH; Kim C; Lee H; Nam D; Lee J; Lee SG; Yang WM; Um JY; Sethi G; Ahn KS
J Cell Physiol; 2017 Feb; 232(2):346-354. PubMed ID: 27177359
[TBL] [Abstract][Full Text] [Related]
12. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
[TBL] [Abstract][Full Text] [Related]
13. STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2.
Zhang D; Liu H; Wang W; Xu G; Yin C; Wang S
Cancer Biol Ther; 2022 Dec; 23(1):1-16. PubMed ID: 36316642
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow mesenchymal stem cells promote head and neck cancer progression through Periostin-mediated phosphoinositide 3-kinase/Akt/mammalian target of rapamycin.
Liu C; Feng X; Wang B; Wang X; Wang C; Yu M; Cao G; Wang H
Cancer Sci; 2018 Mar; 109(3):688-698. PubMed ID: 29284199
[TBL] [Abstract][Full Text] [Related]
15. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
Zheng J; Liu C; Shi J; Wen K; Wang X
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
[TBL] [Abstract][Full Text] [Related]
16. The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway.
Wang J; Jiang C; Li N; Wang F; Xu Y; Shen Z; Yang L; Li Z; He C
Cell Death Dis; 2020 Aug; 11(8):682. PubMed ID: 32826876
[TBL] [Abstract][Full Text] [Related]
17. Repeated radon exposure induced lung injury and epithelial-mesenchymal transition through the PI3K/AKT/mTOR pathway in human bronchial epithelial cells and mice.
Chen H; Chen N; Li F; Sun L; Du J; Chen Y; Cheng F; Li Y; Tian S; Jiang Q; Cui F; Tu Y
Toxicol Lett; 2020 Nov; 334():4-13. PubMed ID: 32949624
[TBL] [Abstract][Full Text] [Related]
18. Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway.
Luo X; Wang J; Lu J; Wang X; Miao Y; Li Q; Li X; Wang L
Biomed Res Int; 2022; 2022():1874550. PubMed ID: 35757470
[TBL] [Abstract][Full Text] [Related]
19. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
20. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis.
Wei R; Xiao Y; Song Y; Yuan H; Luo J; Xu W
J Exp Clin Cancer Res; 2019 Mar; 38(1):112. PubMed ID: 30832706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
